Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials
- Citation:
- Lancet Haematol vol 4 (4) e176-82
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 6
- Parents:
- 2180
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA007968, U10CA033601, U10CA041287, U10CA047559, U10CA077597, U10CA180833, U10CA180836, U10CA180838, U10 CA007968, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA180836, U10 CA041287, U10 CA047559, U10 CA180882, U10 CA180833, U10 CA180838
- Corr. Author:
- Authors:
- Sonali M. Smith Brandelyn N. Pitcher Sin-Ho Jung Nancy L. Bartlett Nina Wagner-Johnston Steven I. Park Kristy L. Richards Amanda F. Cashen Anthony Jaslowski Scott E. Smith Bruce D. Cheson Eric Hsi John P. Leonard
- Networks:
- CAPITAL, IL017, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-MO011, NC002, NY018, WINCORP
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- Alliance-A051201, Alliance-A051202
- Phases:
- 1
- Keywords:
- relapsed lymphoma, PI3K, immunomodulatory agents, rituximab, toxicity